Piper Sandler raised the firm’s price target on Ocular Therapeutix (OCUL) to $31 from $21 and keeps an Overweight rating on the shares. The firm hosted Ocular’s management for an investor dinner after its investor day to discuss the anticipated SOL-1 readout in Q1 2026 and the newly disclosed diabetic retinopathy pivotal trial designs. Given increased confidence in the wet AMD and NPDR Phase 3 programs, Piper raises its peak risk-adjusted sales estimates for AXPAXLI to $3.2B from $1.9B.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OCUL:
- Ocular Therapeutix price target raised to $24 from $17 at Baird
- Buy Rating for Ocular Therapeutix Driven by Strategic Advancements and Promising Clinical Trials in Diabetic Retinopathy
- Ocular Therapeutix: Buy Rating Affirmed Amid Promising Clinical Advancements and Strong Financial Position
- Ocular Therapeutix price target raised to $29 from $20 at Citizens JMP
- Ocular Therapeutix’s Strategic Initiatives and Clinical Advancements Drive Buy Rating